Respiratory Syncytial Virus: Current Progress in Vaccine Development
AbstractRespiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Rudraraju, R.; Jones, B.G.; Sealy, R.; Surman, S.L.; Hurwitz, J.L. Respiratory Syncytial Virus: Current Progress in Vaccine Development. Viruses 2013, 5, 577-594.
Rudraraju R, Jones BG, Sealy R, Surman SL, Hurwitz JL. Respiratory Syncytial Virus: Current Progress in Vaccine Development. Viruses. 2013; 5(2):577-594.Chicago/Turabian Style
Rudraraju, Rajeev; Jones, Bart G.; Sealy, Robert; Surman, Sherri L.; Hurwitz, Julia L. 2013. "Respiratory Syncytial Virus: Current Progress in Vaccine Development." Viruses 5, no. 2: 577-594.